LEUVEN, Belgium, October 21, 2013 /PRNewswire/ --
ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that JETREA ® (ocriplasmin) is nominated for the 2013 Prix Galien USA Award in the Best Biotechnology Product category.
The Prix Galien USA, now in its seventh year, is an international award that recognizes outstanding achievements in improving human health through the development of innovative therapies. The winner is selected by a committee of nine experts in the biomedical industry and academia, including five Nobel Laureates.
JETREA ® is the first and only pharmacological drug approved by the US Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA). ThromboGenics launched the drug in the US in mid-January 2013. The Company employs 100 people in the US, including 35 operating from its US office in Iselin, New Jersey.JETREA ® was approved in the European Union in March 2013. Partner Alcon, a division of Novartis, launched the drug in the UK, its first market in Europe, in April, and is rolling out the drug across Europe. Alcon acquired the rights to commercialize JETREA ® outside the United States in March 2012. Dr Patrik De Haes, CEO of ThromboGenics, said: "We are extremely proud that JETREA ® has been nominated for such a prestigious award. JETREA ® is the first pharmacological drug for the sight-threatening condition symptomatic VMA/VMT, and for the first time may allow treatment for earlier stage of the disease and prevent vision from deteriorating further. ThromboGenics is committed to working with the global retina community to ensure that as many patients as possible can benefit from this innovative drug." JETREA ® contains the active substance ocriplasmin. It is administered through a single intravitreal injection to treat adults with symptomatic VMA. Symptomatic VMA is a progressive, sight-threatening condition. It is caused by the vitreous humour having an abnormally strong attachment to the macula, the central part of the retina (the light sensitive membrane at the back of the eye). The macula provides central vision that is needed for everyday tasks such as driving, reading and recognizing faces.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts